Literature DB >> 2665844

Successful HLA nonidentical bone marrow transplantation in three patients with the leukocyte adhesion deficiency.

F Le Deist1, S Blanche, H Keable, C Gaud, H Pham, B Descamp-Latscha, V Wahn, C Griscelli, A Fischer.   

Abstract

Three consecutive patients with the severe phenotype of leukocyte adhesion deficiency characterized by a defective expression of LFA-1, Mac-1 (CR3), and p150.95 on leukocytes have received HLA partially incompatible bone marrow transplantation (BMT). The degree of HLA incompatibility between related donors and recipients was 2 HLA antigens in one and one full haplotype in the two others. Graft-v-host disease (GVHD) prophylaxis consisted in T-cell depletion of the bone marrow inoculum and a 60-day course of cyclosporin A. A first attempt led to autologous recovery in one patient. The second transplant in this patient and the first transplant in the two others led to stable partial engraftment of lymphocytes and phagocytic cells, as shown by expression of adhesion molecules (LFA-1, Mac-1) on leukocytes and by HLA typing and restriction fragment-length polymorphism studies using minisatellite probes. Although the level of mixed chimerism was lower in one patient (7% to 30% donor cells) and greater than 50% in the two others, recovery of lymphocyte and phagocytic cell functions was sufficient enough to allow the patient to lead a normal life, infection free in the three cases. These patients, now 57, 32, and 19 months post-transplant, are in good condition without any therapy. These results lead us to propose that the LFA-1 molecule plays a role in HLA-incompatible graft rejection, probably by mediating adhesion of cytotoxic T and non-T lymphocytes to their targets.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665844

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Mechanisms and consequences of leukocyte-endothelial interaction.

Authors:  J M Harlan; N B Vedder; R K Winn; C L Rice
Journal:  West J Med       Date:  1991-10

Review 2.  Stem cell transplantation for immunodeficiency.

Authors:  A Fischer; E Haddad; N Jabado; J L Casanova; S Blanche; F Le Deist; M Cavazzana-Calvo
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Leukocyte adhesion deficiency.

Authors:  H Akbari; M M Zadeh
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

4.  Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.

Authors:  Robert A Sokolic; Thomas R Bauer; Yu-Chen Gu; Mehreen Hai; Laura M Tuschong; Tanya Burkholder; Lyn Colenda; John Bacher; Matthew F Starost; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

5.  An in vivo animal model of gene therapy for leukocyte adhesion deficiency.

Authors:  J C Krauss; L A Mayo-Bond; C E Rogers; K L Weber; R F Todd; J M Wilson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 6.  Leucocyte adhesion deficiency.

Authors:  M H el Habbal; S Strobel
Journal:  Arch Dis Child       Date:  1993-10       Impact factor: 3.791

Review 7.  Hematopoetic stem cell transplantation in neutrophil disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic granulomatous disease.

Authors:  Ronit Elhasid; Jacob M Rowe
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

8.  Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency.

Authors:  Waseem Qasim; Marina Cavazzana-Calvo; E Graham Davies; Jeffery Davis; Michel Duval; Gretchen Eames; Nuno Farinha; Alexandra Filopovich; Alain Fischer; Wilhelm Friedrich; Andrew Gennery; Carsten Heilmann; Paul Landais; Mitchell Horwitz; Fulvio Porta; Petr Sedlacek; Reinhard Seger; Mary Slatter; Mary Slatten; Lochie Teague; Mary Eapen; Paul Veys
Journal:  Pediatrics       Date:  2009-03       Impact factor: 7.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.